g2b's flagship product "Viagra" is now in the NDA application process and has already taken the priority review channel, but it will not be available for sale until April next year.

Of course, if it is a drug that is urgently needed on the market to treat epidemic diseases, you can directly ignore the process and "specially" all the way.

As for Viagra, you don’t expect to enjoy this kind of treatment.

Therefore, the main job of the g2b marketing team is to build sales channels, Mobai Pharmaceutical Store owner, and Guo Min’s task is to conduct industry surveys.

As soon as Nan Yi arrived at Guo Min's office, after greetings, Guo Min immediately got to the point.

Guo Min made sufficient preparations for today's performance report.

"Nansheng, the top technology of modern medicine has always been developing in three countries, including Singguo, Eagle Kingdom, and Switzerland. These three countries have basically monopolized the upper level of pharmaceutical technology. If the third biopharmaceutical wants to develop as soon as possible, in addition to relying on self-research and development, it also needs to acquire externally, especially the acquisition of private laboratories and research institutes. Only in this way can we catch up.

During this period, I have conducted more in-depth research on the bio-pharmaceutical market and found that the highest technology in this industry is basically in the hands of some giants."

Guo Min is talking nonsense now. Third, biopharmaceuticals has been established for almost seven years. In recent years, in addition to drug research and industry research, he not only talks about himself, but even Nanyi has memorized the current situation of biopharmaceuticals and the list of major giants.

Even so, Nan Yi still held up his ear and listened carefully.

"If we want to acquire, first of all, the top ten giants can rule out that they have very strong funds and considerable profits. There is no possibility of taking action. If we propose a acquisition rashly, we may establish an enemy.

But there is an exception to one giant, which is Lilly Pharmaceutical. I asked the investigation company to investigate. Lilly Pharmaceutical's financial situation is not very good. Many shareholders already have the idea of ​​selling their shares..."

"Stop." Nan Yi reached out to interrupt Guo Min, "The shareholders already have the idea of ​​selling the shares they have. What evidence does it support?"

Guo Min was stunned for a moment and said, "There are written reports and audio tapes."

"Well, I'll give me a copy when I leave later, you can continue." Nan Yi reached out and signaled.

Guo Minping regained his mood and continued: "If the bid is reasonable, many shareholders will take over their shares. Therefore, I set Eli Lilly Pharmaceutical as our first acquisition target.

As long as it is acquired, in the country, the Third Biopharmaceutical will have a bridgehead. After investing money to upgrade the industry, the next step can be to eat up some other small companies, laboratories, and research institutes."

Nan Yi thought about Guo Min's words. Eli Lilly Pharmaceuticals is not a small company. This company is very powerful. After thinking about it, Nan Yi said to Dunn next to Guo Min: "Deng, you should be more familiar with Eli Lilly Pharmaceuticals. I want to know how many valuable patented drugs are in the company's hands?"

Deng En is Guo Min's deputy. He turned out to be the bottom of the senior management of Johnson & Johnson. Third Biopharmaceutical dug him through a high price for headhunting. He has been working in Third Biopharma for nearly three years and has passed the assessment period.

Dunn stood up and asked Nan Yi very cleverly. Patented medicine is the key to a pharmaceutical company's standing firm.

"Boss, Eli Lilly Pharmaceuticals holds not many patented drugs, only twelve. The board of directors of Eli Lilly is not willing to invest too much money in research and development. However, their twelve patented drugs are daily medications, with good sales, and there is still a long time before the patent expires.

In addition, I don’t agree with Guo’s opinion. The reason why Eli Lilly Pharmaceuticals has had a financial crisis is because the investment in R&D in the previous few years has been too large, so the board of directors began to restrict investment.

Although reducing investment will weaken the competitiveness of Lilly's future, there is no doubt that Lilly's financial situation will improve within one or two years, so I am not optimistic that we can take over this company."

"Okay, sit down."

Nan Yi did not raise any questions, but just signaled Guo Min to continue.

"Nansheng, I have set two second goals, both of which are small institutions, created by two medical professors. Their research directions are both in the field of cancer, the two are Nelson Pharmaceuticals and Peptide Pharmaceuticals.

Both companies are not large in size, but the patented drugs in their hands are quite good. They can be said to be the most advanced drug for treating cancer at present. However, if we want to acquire these two companies, we have to pay a lot of money, which is why they have not been acquired so far."

After Guo Min finished introducing the article, he looked at Nan Yi's face and waited for his questions or questions.

"Can their medicine cure cancer?" Nan Yi asked a question that seemed a bit redundant.

“No, there are currently no drugs that can cure cancer. Their drugs are mainly capable of inhibiting the spread of cancer cells and have smaller side effects than other known drugs, but this does not prevent them from continuing to study in this field;

However, if you want to conduct in-depth research, you need to invest a lot of money, which is not something that the two companies can afford." Guo Min said truthfully, and he himself was very optimistic about the two companies.

"What is the massive amount? If they conduct special research, how much research fund will it cost each year?"

"Nan Sheng, I have conducted a rough statistics. If the two companies continue to conduct special research, the annual funding will be about 30 million US dollars." Guo Min said with certainty.

He has conducted statistics on this aspect.

"Did you consider inflation?"

“Uh, no.”

"If you consider inflation and expand the time span to thirty years, the amount of money you need to spend will not be less than US$2 billion. This investment is too large and you may not see the returns. I need to evaluate the two companies and continue to pay attention until the evaluation report is released."

"clear."

Next, Guo Min proposed some acquisition targets for the third-tier team, and the acquisition targets were some research institutes and private laboratories.

Researchers who can establish private laboratories often hold many patents in their hands. They obtain funds to maintain their research through external authorization of patents in their hands. Usually, these people's research is relatively single and only conducts research in one field.

After acquiring them, they can be integrated. Once two researchers in related fields integrate, they may make breakthroughs in a short period of time. After all, sometimes the one that is stuck in research is a layer of window paper, and after breaking it, there will be great development.

Guo Min has planned a total of 12 acquisition targets for the country, 3 companies and 9 private laboratories. Nanyi has neither affirmed nor denied it. Whether it is suitable for acquisition or not, it will take a month or two to see whether it can be acquired or not.

Next, Guo Min talked about some acquisition targets of other countries:

3 private laboratories and 2 research institutes in Switzerland;

1 company in Faguo, which is engaged in genetic research. Although there is no breakthrough at present, it has great potential in the future. At the same time, it has also set goals for 5 private laboratories;

Two medium-sized pharmaceutical companies in Yingguo can be merged after acquisition to become a large pharmaceutical company, with 5 research institutes and 12 private laboratories, which is more than the Singguo, which shows the strength of Yingguo in the field of biopharmaceuticals;

There are 2 German pharmaceutical companies, 3 research institutes, and 1 East Germany institution that can’t figure out what nature it is, and it’s thanks to Guo Min who was able to find this goal.

Similarly, Nanyi did not immediately make up the acquisition targets of other countries. He had to first investigate whether these companies and institutions are worthy of acquisition, and also measured whether they can acquire and whether there is an opportunity to acquire. There are many factors that need to be considered.

However, no matter which companies will be acquired in the end, it can be foreseen now that g2b will not be able to bring profits to Nanshi in a short period of time, and all the profits will be used as R&D funds, and there is a high probability that Nanshi will continue to subsidize Third Biopharmaceuticals.

Fortunately, Nanyi has been mentally prepared for 30 years since the first day of his decision to invest in the biopharmaceutical field. This time can be said to be very abundant, so it will not be too uncomfortable when Nanyi signs the budget table.

Nanyi’s goal is to diversify its development in genetics, broad-spectrum antibiotics, cancer, respiratory system, cardiovascular and cerebrovascular diseases, and epidemic virology, and strive to be an unshakable leading position in every field.

"Guo Min, let's say this first about the acquisition. Wait for my news before taking the next step. Next, I need you to find a candidate, who will serve as the president of Qiande New Drug Development Company.

Qiande’s main goal is to build a cdmo platform, tract      development     manufacturing     anization, from preclinical research, clinical trials to commercial production stages, in-depth docking with enterprise R&D, procurement, production and other supply chain systems, providing innovative process R&D and large-scale production services for other biological enterprises, replacing pure production capacity output with high added value technology output.

Accepting commissions from other biopharmaceutical companies to carry out customized production services. The businesses covered include drug outsourcing processes, formula development, clinical trial drugs, chemical or biosynthesis raw material production, intermediate manufacturing, powder, injection and other preparation production, and packaging services.

This company should not have any connection with Third Biopharma, profitability is only my most superficial purpose.

Although other pharmaceutical companies will definitely not outsource the most core part, we can still see a little clue from the fragmentary parts, not asking to steal other people's formulas, but only asking to bring us some inspiration."

"Nansheng, your creativity is so good. Outsourcing unimportant work can save a lot of labor costs for biopharmaceutical companies, and can also free researchers from heavy work and concentrate on the core R&D part."

Guo Min first flattered, and then changed the subject, "But, in this way, the burden of labor costs falls on our shoulders, and we cannot make too much profit."

Nan Yi smiled and said, "Guo Min, your thinking should be opened and you should consider it globally. There are many talents in this field, whether in China or India. As long as we pay our salary to RMB 500 or RMB 1,500, I believe that many talents are willing to join Gande for us to drive it."

Guo Min smiled awkwardly and said, "Sorry, my thinking is too narrow, only considering the fact that Yi Guo and Li Jiapo."

"It's okay, cdmo just had a sudden idea. Whether it's feasible is still necessary to verify whether it's feasible. If you ask the financial staff to calculate how much profit margin Gande can have, I don't have high requirements, as long as it's not a waste of work."

Guo Min said disagreeably: "It shouldn't be the difference in personnel costs. I believe Gande's profit should be considerable."

"Well, I have children at home, so I won't have dinner with you. When I came, I reserved a seat for you at the Riverside Park restaurant. The restaurant will send me the bill and enjoy it."

"Thank you, Nansheng."

“thanks, boss.”

"No thanks, you"re   wele."

Nan Yi waved his hand and stepped out of Guo Min's office.

...

At 9:30 pm, when Nan Yi was coaxing his two sons to sleep, in Hsinchu County, Taiwan, Chen Wenchen, the gold-medal investor of the richest man Weiye, took two assistants into the office building of the Institute of Technology Research.

After some negotiations, Chen Wenchen was able to enter the office of Li Jinxiong, director of the Institute of Technology Research.

"Director Li, hello, I am the richest man, Weiye, Chen Wenchen."

As soon as he entered the office, Chen Wenchen walked generously to the opposite side of Li Jinxiong and stretched out his right hand.

Li Jinxiong grabbed Chen Wenchen's hand and smiled and said, "Hello, Mr. Chen, the richest man Weiye is a very well-known investment company in Yiguo. I wonder if he is interested in Lianhua Electronics or Lightmask Co., Ltd. when he comes here this time?"

"Director Li, if possible, Lianhua Electronics, Optical Co., Ltd. and your newly established integrated circuit manufacturing, I want to go and have a look."

"Welcome, of course, welcome. The three companies are all in the science park and are not far away. Mr. Chen, don't worry, try my Dayuling high mountain tea first. This year's new tea grows on a mountain that is 2,600 meters high, and is definitely the top oolong tea."

Li Jinxiong said, and the man walked to the edge of the shelf in a corner of the office, picked up a can of tea and walked back to Chen Wenchen, "Look, the tea leaves are hemispherical, dark green in color, with a faint golden color at the bottom of the leaves, soft buds and leaves, thick meat, high pectin content, two or three leaves in one heart, purely hand-picked to ensure the integrity of the tea."

Chen Wenchen looked at the tea leaves and complimented: "Director Li, it's indeed a good tea. I haven't seen such a good high-altitude tea in a long time. I forgot to introduce it. My hometown is in Hualien County. I stayed until I was a teenager before going to the country with my grandma."

"Oh, Mr. Chen is from this province?"

"I should be considered a native of another province. My grandma is from this province. President Li. Seeing Gaoshan tea evokes my childhood memories, I am impatient to taste its mellow taste."

"Look at me, Mr. Chen, wait a moment, I'll have someone make tea right now." Li Jinxiong apologized, immediately walked to the office door, and shouted outside twice.

Soon, a young man ran over to the office, nodded and bowed to make tea.

Drinking tea and chatting, I spent one morning in Li Jinxiong's office. When it was time for dinner, Li Jinxiong invited Chen Wenchen to eat at the Zhubei Restaurant next to the Industrial Research Institute.

Judging from Li Jinxiong's attitude, he was not busy taking Chen Wenchen to the Science Park for inspection.

Chen Wenchen was not in a hurry. He had the work experience of a bad mass group in his resume. He was responsible for the work in Southeast Asia and had rich communication experience with various bureaucrats;

Not to mention bureaucrats like Li Jinxiong who have become monks halfway through scientific research and management, even warlord-style officials who throw people into the rivers at every turn can easily handle it. If Li Jinxiong wants to go around in circles, let him take care of it.

Integrated circuit manufacturing is the new investment target assigned to him by the company. According to the company's intention, this company must be won and invest as much as possible. This is his main job recently, and he has enough time to spend here.

...

At 10 o'clock in the morning, Nan Yi took his two sons to meet a guest, Hadid, a sales manager from a designer who was sent by Boeing.
To be continued...